With approximately 6.82 billion people living in emerging and developing markets across Asia, Africa and Latin America, low- and middle-income countries (LMICs) present a compelling opportunity for pharmaceutical manufacturers. Yet the potential is paired with a stark dilemma: What to prioritize, when to act and how to navigate the complex landscape of access.
 

For pharma companies seeking to expand their reach, navigating access in these countries is no longer just about market entry but about addressing systemic barriers like pricing constraints, infrastructure limitations, regulatory complexities and fragmented healthcare systems. The question isn’t just how to reach these markets—it’s how to tailor solutions that balance business value with genuine impact and where to focus resources amid varying local needs and challenges.

The stakes are high.

In this white paper we look at strategies that companies can use to navigate the complexities of these markets and contribute to a healthier, more sustainable future.